Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM-EXT: CP101 in recurrent Clostridium Difficile Infection
NCT03497806Phase 2Completed
- Sponsor
- Finch Therapeutics
- Start
- May 2018
- Primary completion
- Dec 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
A Phase 2 trial of CP101 in Clostridium difficile infection (CDI), sponsored by Finch Therapeutics. Started May 2018; status: completed.
02
Drugs
CP101
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT03497806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03497806.